Purpose: To investigate the evaluation of docetaxel plus prednisone for treating hormone-refractory prostate cancer. Methods: 20 patients with hormone-refractory prostate cancer were candidates for the study and received a regimen of docetaxel 75mg/m2 on d1 and prednisone 5mg bid on d1-21. 21days a cycle. Each patient received a chemotherapy for 4-10 cycles. Results: Folow up varied from 8 to 91 weeks, average 56 weeks. 30%(6/20) achieved complete response, 40%(8/20) got partial response, 20%(4/20) had stable disease and 2%(2/20) progressed. Median time to progression was 51.3 weeks(15-78 weeks). Bone pain relieved in 5 out of 8 patients. Median survival time was longer than 12 months. The adverse effects were mild. Conclusion: Docetaxel plus prednisone had a certain effect on hormone-refractory prostate cancer with good tolerance.% 目的探讨多西紫杉醇联合泼尼松治疗内分泌治疗失败前列腺癌的应用价值.方法入选20例激素抵抗性前列腺癌患者,给予多西紫杉醇75mg/m2,第1天；泼尼松5mg bid,第1—2l天,21天为1个周期,每例接受化疗4—10个周期不等.结果本组病例随访8—91周,中位56周.其中30%(6/20)完全缓解,40%(8/20)部分缓解,20%(4/20)稳定,2%(2/20)进展.缓解和稳定患者的PSA进展中位时间是51.3周(15—78周).8例骨痛患者中5例疼痛缓解.中位生存期大于12个月.不良反应可耐受.结论多西紫杉醇联合泼尼松治疗激素抵抗性前列腺癌有较好疗效,不良反应轻.
展开▼
